# R1 Clinical-Safety Review - sertoli_leydig_cell_tumour

VERDICT: APPROVE

goldens changed: no (intended: n/a - KB narrative, no engine/golden touched)
adversarial verdict file: absent (no .verdict.md present to reconcile)

## 1. SAFETY - PASS
No unsafe, misleading, or harm-inducing statement. Curative claims are correctly
scoped to well-differentiated, stage-confined disease and hedged ("usually",
"essentially benign once removed"). Systemic therapy is explicitly reserved for
higher-risk histology / advanced disease, not applied routinely after low-risk
resection. No absolute directive that could cause harm if followed.

## 2. GROUNDING - PASS (with one verification note)
The draft is exemplary in separating DeVita-attributed claims from general
standard of care:
- Attributed to DeVita: surgery usually curative; lymphadenectomy may be omitted
  for sex-cord stromal group absent bulky nodes; inhibin used to monitor the
  related granulosa cell tumour; GnRH-analog response in advanced SLCT.
- Explicitly labelled "general oncology standard, not from DeVita's section":
  THBSO/debulking for high-risk disease, platinum-based adjuvant chemo, no RT,
  androgen-marker + imaging surveillance, DICER1 germline testing.
This is the sourcing discipline R1 requires. No fabricated or outdated regimen.
No named chemotherapy regimen is mis-attributed to DeVita (draft correctly states
DeVita names no specific regimen for SLCT).

IMPORTANT (non-blocking, verify at source-line): the "advanced SLCT may respond
to GnRH analogs" claim is cited as DeVita-specific and is the load-bearing DeVita
systemic statement (appears twice). GnRH-agonist use in ovarian sex-cord stromal
tumours is evidence-thin and more often discussed for granulosa cell tumours.
Confirm this line exists in the SLCT text of the cited edition; if it is not
SLCT-specific, relabel it as general standard rather than DeVita-sourced. The
claim is clinically uncontroversial as a hedged option (managed by gyn-onc MDT),
so this does not block approval.

## 3. DOSE-FREE - PASS
Automated token scan (mg, mg/m2, AUC, /kg, qN, "day N", cycles) returned no
matches. No numeric dose leaked. "Platinum-based combination chemotherapy" carries
no dose.

## 4. SCOPE - PASS
Consistently decision-support, not directive: "appropriate", "reasonable option",
"can reasonably be omitted", plus explicit refer-to-gyn-onc-MDT guidance for
staging, fertility trade-offs, high-risk histology, advanced/recurrent disease,
and suspected DICER1 syndrome.

## 5. ADVERSARIAL FLAGS
No .verdict.md present; nothing to reconcile. Independent read finds no
still-present ungrounded/mis-sourced/scope-creep claim that would force REVISE,
other than the GnRH source-line verification noted above.

## Blocking: none. Important: 1 (GnRH-DeVita attribution source-line check).
